CME Medical to distribute eZono 4000 for use in multiple clinical settings

CME Medical, the market leader in the specialist infusion pump field, is delighted to announce its partnership with eZono, AG, a company that focuses on ultrasound for procedural guidance, to distribute its flagship product the eZono® 4000.

The eZono® 4000 represents a new era of imaging, needle guidance and education. Using revolutionary technology to provide advanced functionality for procedural guidance, with the simplicity and reliability requested and required by clinicians. The eZono® 4000 can be used for a wide range of applications and procedures in multiple clinical settings.

CME Medical’s dedication to patient well-being, alongside its reputation for providing education, support and training across the market makes the organisation an ideal partner for eZono. The Blackpool based company champions innovative healthcare solutions and sees this as a natural extension to its existing portfolio in IV therapy.

The eZGuide FreePlane Navigation within the eZono 4000® is a unique and revolutionary needle guidance system technology that enables clinicians to easily target desired anatomy in or out of plane without any additional hardware or proprietary needles. Thus, reducing costs and improving efficiency and accuracy.

CME Medical is dedicated to educating existing and potential customers on the unique benefits of the eZono® 4000 including:

  • eZGuide FreePlane Navigation with Adaptive Needle Recognition: Proprietary needle guidance technology lets you know exactly where you are in relation to your target.
  • Precision: eZGuide’s technology allows precise needle placement from any plane.
  • Time Savings: eZGuide’s revolutionary needle guidance technology improves efficiency.
  • Customer Education: Cue Card onboard Education offers detailed step by step instructions, along with 3D anatomical illustrations, allowing clinicians to practice as they scan.
  • Clinical Outcomes: Improved accuracy means decreased complications and better outcomes.
  • Cost Savings: eZGuideTM requires no additional expensive hardware, proprietary needles or special gauges
  • Increase patient comfort: Reduction of anxiety and pain.
  • Reduces multiple puncture attempts, thus, potentially reducing infection rates.
  • Reduced risk of infection from needle re-entry.

John Carrington, Managing Director of CME Medical comments:

The eZono® 4000 offers a unique new approach to the patient pathway, and we’re pleased to welcome it into the CME Medical product portfolio to complement our existing range. This gold standard in care benefits both practitioner and patient, creating the safest and most comfortable environment for these procedures. As a leader in the portable infusion sector our existing customers already have exposure to ultrasound products, providing us with a great platform to start educating them about the benefits of the eZono® 4000.

Tracey Byard, General Manager at eZono AG comments:

With CME Medical’s reputation for providing expert training and advice to ensure their products are used safely and effectively, we know we are partnering with a company that shares the same values. Our training with the CME Medical team has already begun and we will continue to work together to increase existing product knowledge. We are committed to working alongside the team to create a network of support, bringing together our knowledge of the ultrasound field with CME Medical’s extensive experience in the infusion sector.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Medicaid patients less likely to receive prenatal heart defect diagnoses